Novartis obtained portfolio-level options for exclusive rights to Hybrozyme-enabled SC formulations, with economics up to ...
The FDA approves zilganersen, the first disease-modifying Alexander disease therapy, offering rare disease developers a trial ...
Novartis's up-to-$3.2 billion licensing deal for Alteogen's ALT-B4 hyaluronidase enzyme is the fourth subcutaneous-conversion ...
On August 31, 2026, Eli Lilly announced it has entered a definitive agreement to acquire Merida Biosciences, a biotechnology ...
Extending CAR T beyond cancer alters risk–benefit calculus, because chronic autoimmune populations have alternative therapies ...
Continuous direct compression can provide a simplified alternative pathway for selected spray-dried dispersion formulations ...
The FDA cleared four notable therapies within the same week in late August, spanning infectious disease, cardiometabolic care ...
Tara Dougal, event director for pharma at Informa Markets and head of CPHI Milan, previews the 2026 show in an interview with ...
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor. PhD, AbbVie, and Swita Singh, PhD, Bristol ...
FDA approves Rasonque (daraxonrasib), the first broad RAS-targeted therapy for metastatic pancreatic cancer, validating RAS ...
In December 2025, FDA announced that it was deploying agentic AI capabilities across the agency. FDA defined these systems as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results